The American Journal of Managed Care

Amivantamab Plus FOLFOX/FOLFIRI Demonstrates Strong, Durable Activity in mCRC

Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...
ascopubs.org

A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer: Efficacy and safety analysis (BOLD-100-001).

Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized ...

Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial

J&J shares positive long-term results of Rybrevant study for RAS/BRAF wild-type metastatic colorectal cancer at ASCO ...
ascopubs.org

Efficacy and safety of arterial FOLFOX chemotherapy plus anti-PD-(L)1 immunotherapy as first-line treatment for unresectable intrahepatic cholangiocarcinoma: A propensity score ...

Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A single-arm, open-label, phase II study (ENLIGHTEN study). This is an ...
The American Journal of Managed Care

Amivantamab Plus Chemotherapy Delivers Durable Responses in RAS/BRAF Wild-Type mCRC: Filippo Pietrantonio, MD

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
Health And Pharma

Amivantamab Plus Chemotherapy Shows Promising Long-Term Responses in Colorectal Cancer

Longer-term follow-up from the Phase 1b/2 OrigAMI-1 study shows that amivantamab (Rybrevant) plus FOLFOX or FOLFIRI achieved ...